Biodesix, Inc. announced a new study published in CHEST Pulmonary Journal reaffirming the effectiveness of its Nodify CDT® blood-based lung nodule test, which assesses seven autoantibodies linked to ...
Background: The Early CDT-Lung test is an assay, intended as a tool for risk stratification in a population at high risk for lung cancer. The test measures autoantibodies (AAb) against a panel of six ...
BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced that WPS Government Health Administrators, ...
BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. a leader in lung cancer diagnostics, is extending its blood-based testing portfolio with the release of the Nodify CDT TM test, designed to help ...
Biodesix, Inc. BDSX recently announced a new post-market clinical validation study, published in CHEST Pulmonary Journal. The study reaffirms the previously established performance of the BDSX’s ...
Deacetylase inhibitor (DACI) panobinostat in relapsed small cell lung cancer (SCLC) patients: Results of a multicenter phase II trial. Phase II trial of R-(-)-gossypol acetic acid (NSC 726190, AT-101) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback